Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. (Q34498728)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

title

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

7

Hidenori Tanaka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Tatsuo Kimura

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Shinzoh Kudoh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Kanako Umekawa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Misato Nagata

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Kuniomi Matsuura

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Shigeki Mitsuoka

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Naruo Yoshimura

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Yukimi Kira

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Toshiyuki Nakai

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Kazuto Hirata

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

language of work or name

English

0 references

publication date

4 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

568

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

19 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Erlotinib in previously treated non-small-cell lung cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536666

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

7 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Cytochrome P450-dependent metabolism of gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-568

Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23207012

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23207012

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23207012

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-12-568

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

19 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

PubMed publication ID

23207012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23207012%20AND%20SRC:MED&resulttype=core&format=json